# Inoviem Scientific

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inoviem-scientific

- Industry: Biotechnology
- Headquarters: Strasbourg, France
- Website: www.inoviem.com
- Total disclosed funding: $0.3M
- Latest round: Seed (May 5, 2015)
- Investors on record: 1

## About

Inoviem Scientific SAS is a Bioanalytical R&D firm that specializes in innovative technologies aimed at advancing drug discovery and clinical development for various therapeutic areas, including oncology and autoimmune disorders.Founded in 2011 and headquartered in Strasbourg, France, Inoviem Scientific SAS focuses on bioanalytical research and development. The company has successfully raised a total of EUR 0.3 mn across three deals, with its latest funding round being a Grant of EUR 0.1 mn from Strasbourg Eurométropole in April 2017. The CEO, Pierre Eftekhari, leads the firm’s strategic direction, contributing to its growth and operational initiatives.Inoviem Scientific offers a comprehensive suite of bioanalytical services that support drug discovery and clinical development. Their core technologies, NPOT® and PIMS®, enable the investigation of drug mechanisms on human tissues, ensuring accurate analysis of molecular structures. Inoviem provides essential services for target validation, patient cohort stratification, and biomarker discovery, catering to pharmaceutical and biotechnology clients globally across North America, Europe, and Asia.Inoviem Scientific generated revenue of EUR 1,237,248.60 in 2018, with an EBITDA of EUR 169,171.90 for the same year. The company’s revenue model is primarily based on B2B service agreements with clients, where costs are determined by the specific scope and complexity of projects undertaken.Inoviem Scientific plans to utilize its recent funding from the EUR 0.1 mn Grant received in April 2017 to enhance its research capabilities and develop new products. The firm is focused on expanding its services into new geographic regions, specifically targeting increased presence in Asian markets by 2025. These initiatives are aimed at addressing unmet medical needs through innovative research and the application of advanced bioanalytical technologies.

## Funding rounds

- Seed, May 5, 2015, $0.3M — Capital Grand Est

## Investors

- Capital Grand Est (https://capitalatlas.ai/funds/capital-grand-est) — Seed